| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Talaris Therapeutics, Inc. | Chief Financial Officer | Common Stock | 68.1K | $1.16M | $16.99 | Jul 3, 2023 | Direct |
| Cullinan Therapeutics, Inc. | Chief Financial Officer | Stock Option (Right to Buy) | 200K | Apr 29, 2024 | Direct | ||
| Oncorus, Inc. | Director | Stock Option (right to buy) | 12.5K | Jun 23, 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| CGEM | Cullinan Therapeutics, Inc. | Apr 29, 2024 | 1 | $0 | 4 | Apr 30, 2024 | Chief Financial Officer |
| CGEM | Cullinan Therapeutics, Inc. | Apr 29, 2024 | 0 | $0 | 3 | Apr 30, 2024 | Chief Financial Officer |
| TALS | Talaris Therapeutics, Inc. | Jul 3, 2023 | 1 | -$39.9K | 4 | Jul 6, 2023 | Chief Financial Officer |
| TALS | Talaris Therapeutics, Inc. | Feb 1, 2023 | 2 | $0 | 4 | Feb 3, 2023 | Chief Financial Officer |
| TALS | Talaris Therapeutics, Inc. | Sep 10, 2022 | 1 | $0 | 4 | Sep 13, 2022 | Chief Financial Officer |
| ONCR | Oncorus, Inc. | Jun 23, 2022 | 1 | $0 | 4 | Jun 24, 2022 | Director |
| TALS | Talaris Therapeutics, Inc. | Feb 1, 2022 | 2 | $13K | 4 | Feb 2, 2022 | Chief Financial Officer |
| ONCR | Oncorus, Inc. | Jun 16, 2021 | 1 | $0 | 4 | Jun 17, 2021 | Director |